Finanztrends
Deine Einschätzung
Was spricht für und gegen Genetic Technologies Ltd. in den nächsten Jahren?
Pro
?
M****
?
U****************
?
A****************
Kontra
?
W******* i* V********
?
M************
?
L*********** I********** f** d** n******* J****
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Genetic Technologies Ltd. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Genetic Technologies Ltd. | - | - | - | - | - | - | - |
| Invion Ltd | 0,00 % | 0,00 % | 0,00 % | -41,67 % | -47,50 % | 4100,00 % | 320,00 % |
| Immutep LTD ADR | -2,34 % | 0,60 % | -9,73 % | -78,86 % | -87,15 % | -82,60 % | -89,36 % |
| Arovella Therapeutics Ltd. | -1,39 % | 2,82 % | -6,41 % | -22,34 % | -12,05 % | 69,77 % | 43,14 % |
Kommentare
News
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path
Key Points
- Interested in Black Diamond Therapeutics, Inc.? Here are five stocks we like better.
- Silevertinib showed encouraging Phase 2 lung cancer data, including a 60% objective response
Pelthos Therapeutics Q1 Earnings Call Highlights
Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment’s third full quarter since launch